| Literature DB >> 29867712 |
Ahreum Baek1,2, Eun Jee Park3, Soo Yeon Kim4, Bae-Geun Nam2,5, Ji Hyun Kim1, Sang Woo Jun6, Sung Hoon Kim1, Sung-Rae Cho2,5,7,8,9.
Abstract
Repetitive transcranial magnetic stimulation (rTMS) can be used in various neurological disorders. However, neurobiological mechanism of rTMS is not well known. Therefore, in this study, we examined the global gene expression patterns depending on different frequencies of repetitive magnetic stimulation (rMS) in both undifferentiated and differentiated Neuro-2a cells to generate a comprehensive view of the biological mechanisms. The Neuro-2a cells were randomly divided into three groups-the sham (no active stimulation) group, the low-frequency (0.5 Hz stimulation) group, and high-frequency (10 Hz stimulation) group-and were stimulated 10 min for 3 days. The low- and high-frequency groups of rMS on Neuro-2a cells were characterized by transcriptome array. Differentially expressed genes were analyzed using the Database of Annotation Visualization and Integrated Discovery program, which yielded a Kyoto Encyclopedia of Genes and Genomes pathway. Amphetamine addiction pathway, circadian entrainment pathway, long-term potentiation (LTP) pathway, neurotrophin signaling pathway, prolactin signaling pathway, and cholinergic synapse pathway were significantly enriched in high-frequency group compared with low-frequency group. Among these pathways, LTP pathway is relevant to rMS, thus the genes that were involved in LTP pathway were validated by quantitative real-time polymerase chain reaction and western blotting. The expression of glutamate ionotropic receptor N-methyl d-aspartate 1, calmodulin-dependent protein kinase II (CaMKII) δ, and CaMKIIα was increased, and the expression of CaMKIIγ was decreased in high-frequency group. These genes can activate the calcium (Ca2+)-CaMKII-cAMP-response element-binding protein (CREB) pathway. Furthermore, high-frequency rMS induced phosphorylation of CREB, brain-derived neurotrophic factor (BDNF) transcription via activation of Ca2+-CaMKII-CREB pathway. In conclusion, high-frequency rMS enhances the expression of BDNF by activating Ca2+-CaMKII-CREB pathway in the Neuro-2a cells. These findings may help clarify further therapeutic mechanisms of rTMS.Entities:
Keywords: Ca2+–calmodulin-dependent protein kinase II–cAMP-response element-binding protein pathway; Neuro-2a cells; brain-derived neurotrophic factor; high-frequency; low-frequency; repetitive magnetic stimulation
Year: 2018 PMID: 29867712 PMCID: PMC5949612 DOI: 10.3389/fneur.2018.00285
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1Experimental design and transcriptome analysis. (A) Undifferentiated Neuro-2a cells. (B) Neuro-2a cells were differentiated for 4 days with 2% fetal bovine serum and retinoic acid in Dulbecco’s Modified Eagle Medium. (C) A timeline of the experimental procedures. (D) A scheme of repetitive magnetic stimulation (rMS) treatment in Neuro-2a cells. The cultured cells were divided into the sham group, the low-frequency group, and the high-frequency groups and were each stimulated over 3 days. (E) Bar graphs show the number of differentially expressed genes with fold change ≥ |1.5| in the high-frequency group compared with the low-frequency group.
Primers used for qRT-PCR.
| Gene symbol | Forward primer (5′ → 3′) | Reverse primer (5′ → 3′) |
|---|---|---|
| CAG GAT CGT CAG | CCA AGC AAC TGA | |
| TGC ACC TGG TAG GGG | GAA TAC AGG GTG GCT | |
| TGC TGC TCT TTC | TCA ATG GTG GTG | |
| TTG TGC GTC TCC | TGT CAT GCT GGT | |
| GGG TCA CAG CGG | ATT GCG AGT TCC | |
| CAT CAC TGC CAC CCA | ATG CCA GTG AGC |
GRIN1, glutamate receptor ionotropic N-methyl-.
The enriched Kyoto Encyclopedia of Genes and Genomes pathways in high-frequency group compared with low-frequency group.
| Term | Count | % | Genes | |
|---|---|---|---|---|
| mmu05031: Amphetamine addiction | 9 | 0.0092 | 0.0009 | FOS, CAMK2G, GRIN1, CAMK2D, PRKACA, FOSB, PPP3CA, CACNA1C, CAMK2A |
| mmu04713: Circadian entrainment | 10 | 0.0102 | 0.0027 | FOS, GNGT2, CAMK2G, GRIN1, CAMK2D, PER1, PRKACA, PER3, CACNA1C, CAMK2A |
| mmu04722: Neurotrophin signaling pathway | 11 | 0.0113 | 0.0037 | PDPK1, RPS6KA1, MAPK14, CAMK2G, PIK3CD, CAMK2D, SH2B2, SH2B1, MAPK7, MAP2K7, CAMK2A |
| mmu04917: Prolactin signaling pathway | 8 | 0.0082 | 0.0063 | FOS, SOCS2, MAPK14, SOCS1, PIK3CD, JAK2, STAT1, STAT3 |
| mmu04725: Cholinergic synapse | 10 | 0.0102 | 0.0070 | FOS, ACHE, GNGT2, CAMK2G, PIK3CD, CAMK2D, PRKACA, JAK2, CACNA1C, CAMK2A |
LTP pathway is relevant to rMS treatment and is shown in a bold fonts.
These pathways are statistically significant (.
FOS, FBJ osteosarcoma oncogene; CAMK2G, calcium/calmodulin-dependent protein kinase II gamma; GRIN1, glutamate receptor ionotropic N-methyl-d-aspartate 1; CAMK2D, calcium/calmodulin-dependent protein kinase type II subunit delta; PRKACA, protein kinase, cAMP dependent, catalytic, alpha; FOSB, FBJ osteosarcoma oncogene B; PPP3CA, protein phosphatase 3, catalytic subunit, alpha isoform; CACNA1C, voltage-dependent L-type calcium channel subunit alpha-1C; CAMK2A, calcium/calmodulin-dependent protein kinase II alpha; GNGT2, guanine nucleotide binding protein (G protein), gamma transducing activity polypeptide 2; PER1, period circadian clock 1; PER3, period circadian protein homolog 3; RPS6KA1, ribosomal protein S6 kinase polypeptide 1; ribosomal protein S6 kinase polypeptide 1; PDPK1, 3-phosphoinositide dependent protein kinase 1; MAPK14, mitogen-activated protein kinase 14; PIK3CD, phosphatidylinositol 3-kinase catalytic delta polypeptide; SH2B2, SH2B adaptor protein 2; SH2B1, SH2B adapter protein 1 isoform 3; MAPK7, mitogen-activated protein kinase 7; MAP2K7, dual specificity mitogen-activated protein kinase kinase 7; SOCS2, suppressor of cytokine signaling 2; SOCS1, suppressor of cytokine signaling 1; JAK2, Janus kinase 2; STAT1, signal transducer and activator of transcription 1; STAT3, signal transducer and activator of transcription 3; ACHE, acetylcholinesterase precursor.
Figure 2Validation of mRNA expression and protein quantification using qRT-PCR and western blot analysis in undifferentiated Neuro-2a cells. (A) The relative mRNA expression of target genes was normalized by sham expression and was calculated using the 2−ΔΔCt method by qRT-PCR. All results are expressed as means ± SEM. (B) Western blot analysis was performed using antibodies against calmodulin-dependent protein kinase II (CaMKII), phospho-cAMP response element binding (p-CREB), and actin (a control). All results are expressed as means ± SEM. (C) Comparison of relative protein expression for CaMKII, p-CREB, and actin (a control) with Multi Guage (v3.0) software (Fujifilm). *p < 0.05, **p < 0.01, and ***p < 0.001 comparison with the sham group in undifferentiated Neuro-2a cells. ###p < 0.001 comparison with the low-frequency group in undifferentiated Neuro-2a cells.
Figure 3Validation of mRNA expression and protein quantification using qRT-PCR and western blot analysis in differentiated Neuro-2a cells. (A) The relative expression of target genes was normalized by sham expression and was calculated using the 2−ΔΔCt method by qRT-PCR during neuronal differentiation of Neuro-2a cells. (B) Western blot analysis was performed with calmodulin-dependent protein kinase II (CaMKII), phospho-cAMP response element binding (p-CREB), and actin (as a control) antibodies in the Neuro-2a cells. (C) Comparison of relative protein expression for CaMKII, p-CREB, and actin (a control) in differentiated Neuro-2a cells using Multi Guage (v3.0) software (Fujifilm). All results are expressed as means ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 comparison with the sham group in differentiated Neuro-2a cells. #p < 0.05 and ###p < 0.001 comparison with the low-frequency group in the Neuro-2a cells.
Figure 4Repetitive magnetic stimulation treatment increased brain-derived neurotrophic factor (BDNF) expression in undifferentiated Neuro-2a cells. (A) The relative mRNA expression of BDNF was normalized by sham expression and was calculated using the 2−ΔΔCt method by qRT-PCR. All results are expressed as means ± SEM. (B) Western blot analysis was performed using antibodies against BDNF, and actin (a control). (C) Comparison of relative protein expression for BDNF and actin (a control) with Multi Guage (v3.0) software (Fujifilm). All results are expressed as means ± SEM. ***p < 0.001 comparison with the sham group in undifferentiated Neuro-2a cells. ###p < 0.001 comparison with the low-frequency group in undifferentiated Neuro-2a cells.
Figure 5Repetitive magnetic stimulation treatment increased brain-derived neurotrophic factor (BDNF) expression in differentiated Neuro-2a cells. (A) The relative expression of BDNF was normalized by sham expression and was calculated using the 2−ΔΔCt method by qRT-PCR during neuronal differentiation of Neuro-2a cells. (B) Western blot analysis was performed using BDNF, and actin (as a control) antibodies in the Neuro-2a cells. (C) Comparison of relative protein expression for BDNF and actin (a control) in differentiated Neuro-2a cells with Multi Guage (v3.0) software (Fujifilm). All results are expressed as means ± SEM. ***p < 0.001 comparison with the sham group in differentiated Neuro-2a cells. ###p < 0.001 comparison with the low-frequency group in the Neuro-2a cells.
Figure 6Potential therapeutic mechanisms for high-frequency repetitive magnetic stimulation (rMS) in both undifferentiated and differentiated Neuro-2a cells. The long-term potentiation pathway was confirmed to be an enriched relevant Kyoto Encyclopedia of Genes and Genomes pathway in high-frequency rMS stimulation in both undifferentiated and differentiated Neuro-2a cells. In addition, high-frequency rMS can activate the Ca2+–calmodulin-dependent protein kinase II (CaMKII)–cAMP-response element-binding protein (CREB) signaling pathway. In addition, phospho-CREB and brain-derived neurotrophic factor (BDNF) expression was increased via activation of the Ca2+–CaMKII–CREB signaling pathway in both undifferentiated and differentiated Neuro-2a cells. NMDAR, N-methyl-d-aspartate receptors; CaMKII, Ca2+–calmodulin-dependent protein kinase II; CREB, cAMP-response element-binding protein; CRE, cAMP-response element; BDNF, brain-derived neurotrophic factor.